Business
UroGen Appoints Chris Degnan as Chief Financial Officer
Mr. Degnan has extensive experience in financial strategy, investor relations, SEC reporting, accounting and compliance PRINCETON, N.J.--(BUSINESS WIRE)--
About this update from Urogen Pharma Ltd.
[{"type":"text","content":"\nMr. Degnan has extensive experience in financial strategy, investor relations, SEC reporting, accounting and compliance\n\n PRINCETON, N.J.--(BUSINESS WIRE)--\nUroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that Chris Degnan has been appointed Chief Financial Officer. Mr. Degnan succeeds Don Kim, who is leaving UroGen to pursue other opportunities.\n\n\"Under Don's financial stewardship, we have strengthened our financial position and achieved significant milestones, which include multiple capital raises and investing in the potential commercial launch of UGN-102 for low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC). On behalf of UroGen, I would like to express our deepest gratitude to Don for his dedication. We thank him for the role he has played in our success and wish him the very best in his future endeavors,\" said Liz Barrett, President and Chief Executive Officer, UroGen.\n\n\"As we look to the next stage of growth for UroGen, we are excited to welcome Chris to the leadership team,\" continued Ms. Barrett. \"We are confident that his biotech expertise and strategic insight will be instrumental as we prepare to launch UGN-102, our potential first-in-class product for the treatment of LG-IR-NMIBC and a key component in our strategy to build long-term growth for our company.\"\n\n\"I am thrilled to be joining UroGen at such a pivotal time. I look forward to working with the team to build on the strong financial foundation and drive continued success in bringing new treatment options to patients with urological cancers,” said Chris Degnan.\n\nMr. Degnan joins UroGen with extensive experience as a publicly traded biotech CFO, most recently at Galera Therapeutics and Verrica Pharmaceuticals. Mr. Degnan has broad expertise in financial strategy, investor relations, SEC reporting, accounting and compliance. Earlier in his career, Mr. Degnan held senior positions at Endo International plc. Before joining Endo, Mr. Degnan spent more than 10 years at AstraZeneca plc, a global biopharmaceutical company. He is a Certified Public Accountant in the State of Pennsylvania (voluntary inactive status) and holds a B.S. degree in Accounting from the University of Notre Dame.\n\nIn co...